文献速递炎症性肠病

经典药物在新药时代:1016例炎症性肠病患者硫嘌呤单药治疗的真实世界长期结局

Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-07-06

该研究基于人群基础的IBD South-Limburg队列,纳入1991至2014年间开始硫嘌呤单药维持治疗的1016例炎症性肠病患者(643例克罗恩病,373例溃疡性结肠炎),评估长期有效性和安全性。结果显示,克罗恩病1、5、10年有效率分别为64%、45%、32%,溃疡性结肠炎分别为66%、41%、36%,生物制剂时代前后无显著差异;记录了16例非黑色素瘤皮肤癌、5例淋巴瘤、1例尿路癌和2例门静脉高压。结论认为在真实世界实践中,硫嘌呤单药治疗对克罗恩病或溃疡性结肠炎患者仍然有效、安全且持久,包括在生物制剂时代。

要点

  • 克罗恩病1、5、10年有效率分别为64%、45%、32%,溃疡性结肠炎分别为66%、41%、36%。
  • 生物制剂时代前后有效率无显著差异(克罗恩病p=0.56,溃疡性结肠炎p=0.43)。
  • 记录了16例非黑色素瘤皮肤癌、5例淋巴瘤、1例尿路癌和2例门静脉高压。

核心结论

  • 在真实世界实践中,硫嘌呤单药治疗对克罗恩病或溃疡性结肠炎患者仍然有效、安全且持久,包括在生物制剂时代。

研究设计与样本

  • 基于人群基础的IBD South-Limburg(IBDSL)队列,纳入1991至2014年间开始硫嘌呤单药维持治疗的所有患者,共1016例(643例克罗恩病,373例溃疡性结肠炎)。

主要发现

  • 硫嘌呤单药治疗开始于诊断后中位15.2(Q1-Q3 4.2-48.5)个月。
  • 克罗恩病1、5、10年有效率分别为64%、45%、32%,溃疡性结肠炎分别为66%、41%、36%。
  • 按开始治疗年代分层(生物制剂前 vs 生物制剂时代),有效率无统计学显著差异(克罗恩病p=0.56;溃疡性结肠炎p=0.43)。
  • 记录到16例非黑色素瘤皮肤癌(发病率[IR] 3.33/1000 PY)、5例淋巴瘤(IR 1.04/1000 PY)、1例尿路癌(IR 0.21/1000 PY)和2例门静脉高压。

关键数值与推荐

  • 治疗有效定义为治疗期间无升级至生物制剂、无皮质类固醇疗程、无手术、无因活动性疾病住院。
  • 长期有效性通过Kaplan-Meier分析校正随访差异进行评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thiopurines remain recommended as maintenance therapy in patients with inflammatory bowel disease (IBD). Despite their widespread use, long-term effectiveness data are sparse and safety is an increasingly debated topic which thwarts proper delineation in the current IBD treatment algorithm. AIMS: To document effectiveness and safety of thiopurine monotherapy in patients with IBD, using the population-based IBD South-Limburg (IBDSL) cohort METHODS: All patients starting thiopurine monotherapy as maintenance between 1991 and 2014 were included. Therapy was defined as effective if there was no escalation to biologicals, no course of corticosteroids, no surgery and no hospitalisation for active disease during treatment. Long-term effectiveness was assessed by adjusting for differences in follow-up using Kaplan-Meier analyses. Mid- to long-term safety regarding cancer incidence and clinically relevant liver disease was documented. RESULTS: In total, 1016 patients (643 Crohn's disease [CD]; 373 ulcerative colitis [UC]) received thiopurine monotherapy at a median of 15.2 (Q1-Q3 4.2-48.5) months after diagnosis. During follow-up, effectiveness rates at 1, 5 and 10 years were 64%, 45%, 32%, respectively, in CD and and 66%, 41%, 36%, respectively in UC. No statistically significant differences in effectiveness were observed after stratification for era of initiation (pre-biological vs biological, CD: p = 0.56; UC: p = 0.43). Sixteen non-melanoma skin cancers (incidence rate [IR] 3.33/1000 PY), five lymphomas (IR 1.04/1000 PY) and one urinary tract cancer (IR 0.21/1000 PY) were recorded. Two cases of portal hypertension were identified. CONCLUSION: In real-world practice, thiopurine monotherapy remains effective, safe and durable for patients with CD or UC, including in the era of biologics.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rezazadeh Ardabili A, Jeuring S, Mujagic Z, et al. Classic drugs in the time of new drugs: real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 35794735. doi:10.1111/apt.17128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。